why choose us

First received: October 30, 2024

Clinical Trial: Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Healthy Participants

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-label, Single-site, Randomized, Single-dose, Two-Period, Crossover Study to Assess the Relative Bioavailability of GP681 Powder for Oral Suspension and Tablet Formulations in Healthy C

Brief Summary: The primary objective is to evaluate the relative bioavailability and pharmacokinetic profile of a single oral dose of the test formulation, GP681 Powder for Oral Suspension (20 mg/sachet), compared to the reference formulation, GP681 tablet (20 mg/tablet), in healthy Chinese male subjects.The secondary objectives are to assess the safety of a single oral dose of the GP681 Powder for Oral Suspension (20 mg/sachet) and GP681 tablet (20 mg/tablet) in healthy Chinese male subjects, as well as the…

Read more